We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing

By LabMedica International staff writers
Posted on 06 Feb 2024
Image: The cobas Mass Spec solution for clinical labs (Photo courtesy of Roche Diagnostics)
Image: The cobas Mass Spec solution for clinical labs (Photo courtesy of Roche Diagnostics)

Mass spectrometry, known for its higher sensitivity and specificity compared to immunoassays, is particularly effective for testing molecules like Vitamin D and certain hormones where antibody-based tests struggle to differentiate between similar forms. This method allows for more precise testing. Researchers and clinicians have been investigating the use of mass spectrometry for such assays for several years. However, due to its complexity compared to standard immunoassays, mass spectrometry has largely been limited to large clinical reference laboratories and specialized testing companies that have the necessary resources and expertise to develop and conduct these tests. Now, a fully automated clinical mass spectrometry system being developed for routine lab testing could change that.

Roche Diagnostics (Basel, Switzerland) is currently developing a fully automated, standardized liquid chromatography-mass spectrometry (LC-MS) solution that will seamlessly integrate into existing clinical chemistry and immunochemistry testing as part of its cobas Pro integrated solutions, as well as laboratory automation and IT systems. Roche had recently provided a glimpse of its upcoming mass spectrometry analyzer, cobas Mass Spec, at EuroMedLab 2023. The Roche instrument, slated to be a complete automated sample-to-answer system, is designed to offer an experience similar to using traditional clinical analyzers. Additionally, the system will feature intelligent software to provide fully integrated results, setting the cobas Mass Spec apart from current mass spectrometry analyzers used in various laboratories. The instrument is expected to offer a wide in-vitro diagnostics (IVD) testing menu and replicate the user experience of conventional immunoassay or clinical chemistry analyzers.

The cobas Mass Spec will be incorporated into Roche's existing cobas Pro integrated solutions analyzer, tailored for mid- to high-throughput laboratories. This integration will facilitate its incorporation into existing laboratory workflows. The full integration with the cobas Pro chemistry and immunochemistry analyzers could allow labs to establish workflows where positive samples from initial screenings, like drugs-of-abuse tests, are automatically confirmed using the mass spec analyzer. Automated mass spec analysis would be particularly beneficial in toxicology and endocrine testing, where it can overcome interference issues often encountered in immunoassay testing. The system is anticipated to appeal to both smaller laboratories looking to adopt mass spec-based testing without existing expertise and larger labs, such as national laboratories, which may view the new instrument as an opportunity to streamline their operations. Roche reportedly plans to launch the cobas Mass Spec in 2024, initially in the EU, followed by releases in the US and China.

Related Links:
Roche Diagnostics

Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Hybrid Pipette
SWITCH
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more